Third Rock Ventures has established its third biotech fund in 6 years, bringing in a haul of $516 million for one of the most active groups of early-stage biotech investors in the world. The new fund, which brings the total it's raised to a whopping $1.3 billion-plus, will be used to launch another 16 or so drug developers.
Alta Partners has jumped into the venture syndicate, joining prolific biotech investor Third Rock and its high-profile colleagues at Atlas Venture, which are gambling that beloranib, which inhibits the MetAP2 enzyme, can set a whole new standard for weight-loss treatments.
Cambridge, MA-based Zafgen has taken another big step forward in its quest to develop a unique new weight drug. The biotech has laid out its plans for its first Phase IIa study of beloranib, which inhibits the MetAP2 enzyme.
The trend could create a wealth of opportunities for the developers because of the blockbuster market for weight drugs, one that Big Pharma is unlikely to neglect despite past failures with anti-obesity meds.
In yet another sign of just how quickly biotech investors can change their minds, Bloomberg is running a piece today speculating on which Big Pharma company is most likely to swoop in and pay a big...
No one working in the drug development world would be surprised to hear that some of the biggest pharma companies in the world have had a colossal meltdown on the R&D side of the business. The
Cambridge-based upstart Zafgen has rounded up $33 million in a third venture round as it sets out to prove in an upcoming mid-stage trial that it has a viable therapeutic alternative to bariatric
Undaunted by the FDA's ever-rising safety bar for obesity drugs, Cambridge, MA-based Zafgen today partially pulled back the veil from some early-stage data on its lead weight drug, demonstrating that
Hey, it's not all bad news out there. Despite the drumbeat of reports on the fallout from the credit crisis, two more biotechs report lining up new rounds. A new regulatory filing reveals that Pacira